TABLE 2.
SPRR3 loss results in reduced adverse cardiac remodeling and preserved mouse cardiac function from TAC (Day 7 to day 60). Sprr3−/− mice showed significant improvement in cardiac ejection fraction (EF) and reduction in adverse cardiac remodeling measured by LVIDd and LVIDs
| Echo parameters | WT mice | Sprr3−/− mice | P values | |
|---|---|---|---|---|
| LVIDD (mm) | D7 | 3.473 ± 0.47 | 3.454 ± 0.25 | ns; P = .97 |
| D60 | 3.739 ± 0.35 | 3.437 ± 0.25 | ns; P = .098 | |
| LVIDS (mm) | D7 | 1.916 ± 0.30 | 1.883 ± 0.23 | ns; P = .98 |
| D60 | 2.249 ± 0.34 | 1.944 ± 0.17 | *P = .03 | |
| EF | D7 | 78.62 ± 4.29 | 78.85 ± 4.95 | ns; P = .81 |
| D60 | 73.15 ± 3.35 | 77.03 ± 2.92 | *P = .019 | |
| FS% | D7 | 44.9 ± 3.16 | 45.61 ± 3.44 | ns; P = .66 |
| D60 | 40.14 ± 3.59 | 43.46 ± 2.36 | *P = .019 | |
| ΔLVIDD% | 8.637 ± 12.95 | −0.4488 ± 4.072 | *P = .0421 | |
| ΔLVIDS% | 19.16 ± 21.82 | 3.80 ± 8.02 | *P = .050 | |
| ΔEF% | −10.38 ± 9.81 | −4.29 ± 8.00 | *P = .024 | |
| ΔFS% | −6.72 ± 6.13 | −2.10 ± 4.51 | ns; P = .069 | |
| N | 14 | 8 | ||
| Measured echo values | ||||
|---|---|---|---|---|
| LVIDD | ||||
| D7 | D60 | |||
| WT | SPRR3−/− | WT | SPRR3−/− | |
| 3.157 | 3.510 | 3.877 | 3.585 | |
| 3.076 | 3.748 | 3.368 | 3.680 | |
| 3.606 | 3.531 | 4.190 | 3.687 | |
| 3.361 | 3.443 | 3.483 | 3.395 | |
| 3.565 | 3.769 | 3.707 | 3.504 | |
| 3.280 | 3.314 | 3.823 | 3.483 | |
| 3.015 | 2.970 | 3.252 | 2.900 | |
| 2.988 | 3.350 | 3.280 | 3.260 | |
| 4.339 | 3.544 | |||
| 3.653 | 3.877 | |||
| 4.150 | 3.980 | |||
| 3.090 | 4.050 | |||
| 3.710 | 3.470 | |||
| 3.640 | 4.450 | |||
| Average | 3.473 | 3.454 | 3.739 | 3.437 |
| LVIDS | ||||
|---|---|---|---|---|
| D7 | D60 | |||
| WT | SPRR3−/− | WT | SPRR3−/− | |
| 1.718 | 1.759 | 2.281 | 2.003 | |
| 1.704 | 2.288 | 1.908 | 2.180 | |
| 2.098 | 1.996 | 2.662 | 2.085 | |
| 1.793 | 1.820 | 2.064 | 1.847 | |
| 2.010 | 2.098 | 2.186 | 1.942 | |
| 1.779 | 1.813 | 2.152 | 1.894 | |
| 1.636 | 1.570 | 1.854 | 1.610 | |
| 1.616 | 1.720 | 1.827 | 1.990 | |
| 2.478 | 2.085 | |||
| 2.091 | 2.275 | |||
| 2.580 | 2.500 | |||
| 1.630 | 2.650 | |||
| 1.840 | 2.030 | |||
| 1.850 | 3.010 | |||
| Average | 1.916 | 1.883 | 2.249 | 1.944 |
| Ejection fraction | ||||
|---|---|---|---|---|
| D7 | D60 | |||
| WT | SPRR3−/− | WT | SPRR3−/− | |
| 78.263 | 82.131 | 72.679 | 76.293 | |
| 77.304 | 70.160 | 75.655 | 72.419 | |
| 73.691 | 75.618 | 66.615 | 75.470 | |
| 79.154 | 79.550 | 72.575 | 78.032 | |
| 75.758 | 76.333 | 72.687 | 76.848 | |
| 78.308 | 77.788 | 75.600 | 77.962 | |
| 78.547 | 83.800 | 75.399 | 82.800 | |
| 78.769 | 85.400 | 76.786 | 76.400 | |
| 74.255 | 73.035 | |||
| 74.713 | 72.883 | |||
| 74.700 | 74.100 | |||
| 84.200 | 70.300 | |||
| 86.800 | 78.500 | |||
| 86.200 | 67.300 | |||
| Average | 78.619 | 78.847 | 73.151 | 77.028 |
| Fraction shortening% | ||||
|---|---|---|---|---|
| D7 | D60 | |||
| WT | SPRR3−/− | WT | SPRR3−/− | |
| 45.591 | 49.903 | 41.156 | 44.129 | |
| 44.592 | 38.949 | 43.347 | 40.775 | |
| 41.808 | 43.462 | 36.467 | 43.462 | |
| 46.667 | 47.140 | 40.741 | 45.600 | |
| 43.619 | 44.324 | 41.026 | 44.574 | |
| 45.756 | 45.287 | 43.695 | 45.614 | |
| 45.721 | 47.100 | 43.006 | 44.500 | |
| 45.909 | 48.700 | 44.306 | 39.000 | |
| 42.880 | 41.188 | |||
| 42.751 | 41.331 | |||
| 37.800 | 37.200 | |||
| 47.300 | 34.600 | |||
| 50.300 | 41.500 | |||
| 49.300 | 32.400 | |||
| Average | 44.999 | 45.608 | 40.140 | 43.457 |
Data presented in the top eight rows represent ± SD values for echo parameters at day 7 and day 30. In the bottom four rows, the data represent ± SD percent difference (Δ) between day 7 and day 60 for an average of n = 14 for WT mice and n = 8 for Sprr3−/− mice. All the measured echo values are presented separately (below). Statistical difference between cardiac parameters was determined by nonparametric Mann‐Whitney test; P < .05 was considered significant.